Journal Watch · Journal of Clinical Oncology · 2026

Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005.

No unexpected safety signals with concurrent atezolizumab were observed.<h4>Conclusion</h4>Concurrent and adjuvant atezolizumab with chemoradiation did not improve survival in patients with LS-SCLC.

Higgins KA, Hu C, Ross HJ et al.Journal of Clinical Oncology4 min readPharma relevance 75/100

DOI: 10.1200/jco-25-01569PMID: 41529214Study type: randomised / controlled clinical trial

TL;DR

No unexpected safety signals with concurrent atezolizumab were observed.<h4>Conclusion</h4>Concurrent and adjuvant atezolizumab with chemoradiation did not improve survival in patients with LS-SCLC.

Key findings

  • The median DMFS was 13.0 months (95% CI, 11.3 to 18.2) for the CRT-alone arm and 16.8 months (95% CI, 12.1 to 21.6) for the CRT + atezolizumab arm (HR, 0.96 [95% CI, 0.76 to 1.21]).
  • No unexpected safety signals with concurrent atezolizumab were observed.<h4>Conclusion</h4>Concurrent and adjuvant atezolizumab with chemoradiation did not improve survival in patients with LS-SCLC.

Numbers at a glance (from the abstract)

95%

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

Secondary end points included investigator-assessed progression-free survival (PFS), objective response rate, local control, and distant-metastasis-free survival (DMFS).<h4>Results</h4>patients were randomly assigned from May 2019 to December 2023. The median OS was 36.1 months (95% CI, 28.1 to 42.5) for the CRT-alone arm and 31.1 months (95% CI, 28.5 to 44.7) for the CRT + atezolizumab arm, respectively (hazard ratio [HR], 1.03 [95% CI, 0.80 to 1.32]). The median PFS was 11.4 months (95% CI, 10.3 to 13.2) for the CRT-alone arm and 12.1 months (95% CI, 10.9 to 15.2) for the CRT + atezolizumab arm, respectively (HR, 0.98 [95% CI, 0.79 to 1.22]).

Full abstract (original)

Background: <h4>Purpose</h4>NRG Oncology/Alliance LU005 (ClinicalTrials.gov identifier: NCT03811002) tested the addition of atezolizumab to concurrent chemoradiation (CRT) in this open-label, phase III international trial.<h4>Methods</h4>Patients with limited-stage small cell lung cancer (LS-SCLC), stage Tx-IV, N0-3, and M0 with Eastern Cooperative Group performance status (PS) 0-2 received one cycle of chemotherapy (platinum/etoposide) before study registration and were randomly assigned to CRT alone versus CRT plus concurrent and adjuvant atezolizumab, 1,200 mg once daily, every 3 weeks until investigator-assessed progression or intolerable side effects for a maximum of 17 cycles. Patients were stratified by choice of chemotherapy (cisplatin <i>v</i> carboplatin), radiation fractionation schedule (66 Gy once daily <i>v</i> 45 Gy twice daily), sex, and PS (0/1 <i>v</i> 2). The primary end point was overall survival (OS).

What they did: Secondary end points included investigator-assessed progression-free survival (PFS), objective response rate, local control, and distant-metastasis-free survival (DMFS).<h4>Results</h4>patients were randomly assigned from May 2019 to December 2023. The median OS was 36.1 months (95% CI, 28.1 to 42.5) for the CRT-alone arm and 31.1 months (95% CI, 28.5 to 44.7) for the CRT + atezolizumab arm, respectively (hazard ratio [HR], 1.03 [95% CI, 0.80 to 1.32]). The median PFS was 11.4 months (95% CI, 10.3 to 13.2) for the CRT-alone arm and 12.1 months (95% CI, 10.9 to 15.2) for the CRT + atezolizumab arm, respectively (HR, 0.98 [95% CI, 0.79 to 1.22]).

Results & conclusions: The median DMFS was 13.0 months (95% CI, 11.3 to 18.2) for the CRT-alone arm and 16.8 months (95% CI, 12.1 to 21.6) for the CRT + atezolizumab arm (HR, 0.96 [95% CI, 0.76 to 1.21]). No unexpected safety signals with concurrent atezolizumab were observed.<h4>Conclusion</h4>Concurrent and adjuvant atezolizumab with chemoradiation did not improve survival in patients with LS-SCLC.

Abstract © the authors / Journal of Clinical Oncology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1200/jco-25-01569 · PubMed 41529214.

Why it matters for pharma & biotech

  • Relevant to Pharmacology & Drug Discovery teams tracking Journal of Clinical Oncology for new targets, mechanisms and biomarkers.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this Journal of Clinical Oncology study find?

No unexpected safety signals with concurrent atezolizumab were observed.<h4>Conclusion</h4>Concurrent and adjuvant atezolizumab with chemoradiation did not improve survival in patients with LS-SCLC.

What type of study is this?

It is a randomised / controlled clinical trial, published in Journal of Clinical Oncology in 2026. Secondary end points included investigator-assessed progression-free survival (PFS), objective response rate, local control, and distant-metastasis-free survival (DMFS).<h4>Results</h4>patients were randomly assigned from May 2019 to December 2023.

Where can I read the original paper?

The original is at the publisher via DOI 10.1200/jco-25-01569. PubMed ID: 41529214. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Higgins KA, Hu C, Ross HJ et al.. Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005.. Journal of Clinical Oncology (2026). DOI: 10.1200/jco-25-01569.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/chemoradiation-atezolizumab-in-limited-stage-small-cell-lung-cancer-resu-501569/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides